Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 31Cisplatin 21pembrolizumab 8Fluorouracil 6Oxaliplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Taxes 4Albumin-Bound Paclitaxel 4pemigatinib 3infigratinib 3atezolizumab 3Specimen Handling 3Radiosurgery 3Platinum 3Magnetic Resonance Spectroscopy 3Leucovorin 3Carboplatin 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2trametinib 2olaparib 2ivosidenib 2derazantinib 2cobimetinib 2Trastuzumab 2Radiotherapy 2Panitumumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cholangiocarcinoma × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡